Current IBD clinical challenges, emerging therapies, and case-based discussions on what a clinician should do #Gastroenterology
David T. Rubin, MD, FACG; Aline Charabaty, MD; Russell D. Cohen, MD, FACG; Jean-Frederic Colombel, MD; Raymond K. Cross, Jr., MD, MS; Sushila Dalal, MD; Stephen B. Hanauer, MD, FACG; David P. Hudesman, MD, NYU; Jennifer Labas, RN, MSN, FNP-BC
This event offers
6.5 CME credits
CE accredited by Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education.
Interested In Attending This Event?
Additional Registration Information:
One Day IBD Event For NPs and HCPs who treat IBD
See Faculty and Agenda: http://clinicalchallengesinibd.com
Cost: Only $129
Clinical Challenges and Emerging Therapies in IBD is a one-day event designed for clinicians involved in the therapeutic management of patients with inflammatory bowel diseases. Moderated by David T. Rubin, MD, FACG, AGAF, this one-day event will include four interactive sessions.
Who Should Attend
This educational activity is specifically designed for NP's and other healthcare professionals involved and/or interested in the therapeutic management of patients with IBD.
After successful completion of this activity, participants should be able to:
- Assess the mechanism of action and therapeutic potential of evolving treatments in IBD
- Evaluate strategies for sequencing therapeutics in the era of biologics, immunotherapies and biosimilars
- Identify a personalized therapeutic approach to optimally manage complex cases of CD
- Interpret pivotal clinical trial data and novel management strategies for integration into clinical practice
- Describe therapeutic strategies designed to prevent infections and extraintestinal manifestations in IBD
- Define the role of treat-to-target in IBD regimens designed to maximize the opportunity to achieve remission and avoid relapse
- Identify strategies to de-escalate therapy once remission is achieved in IBD
- Assess the emerging role of biosimilars in IBD therapy, and their integration into current standards of care
*In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.